Home
How It Works
Solutions
Resources
Events
Blog
Case Studies
For Academic Experts
Sign Up
Login

Work with thought leaders and academic experts in oncology

Companies can greatly benefit from working with an expert in the field of Oncology. Here are a few reasons why: 1. Cutting-edge Research: Oncology experts stay updated with the latest advancements in cancer research, providing valuable insights and innovative solutions. 2. Clinical Trials: Collaborating with an Oncology researcher allows companies to conduct clinical trials, accelerating the development of new treatments and therapies. 3. Expertise in Precision Medicine: Oncology researchers specialize in personalized medicine, helping companies develop targeted therapies based on individual patient characteristics. 4. Access to Networks: Academic researchers in Oncology have extensive networks within the medical community, providing access to key opinion leaders, clinicians, and other experts. 5. Regulatory Compliance: Oncology experts are well-versed in regulatory requirements, ensuring companies meet all necessary guidelines and standards.

Researchers on NotedSource with backgrounds in oncology include Ping Luo, Dr. Everson A Nunes, Ph.D., Dr. Shilpa Patil, Ph.D, Boris Leibovitch, Luca Delfinis, Dr. Michael W. Craige, PhD, MBA, Dushani L. Palliyaguru, Ph.D., Michael W Harman, Burcu Vitrinel, Ph.D., John M Baust, Ph.D, Garrett A. Perchetti, Research Scientist - Virology, and Jeffrey Townsend.

Ping Luo

Toronto, Ontario, Canada
Bioinformatics Specialist at Princess Margaret Cancer Centre with experience in deep learning
Research Interests (22)
single-cell genomics
deep learning
complex network analysis
Genetics (clinical)
Genetics
And 17 more
About
8 years of science and engineering experience integrating multi-omics data to identify biomarkers for cancer studies. Seeking to apply data analytics expertise to develop new diagnosis and treatment strategies.

See Full Profile

Dr. Everson A Nunes, Ph.D.

Hamilton, Ontario, Canada
Post-Doctoral Fellow at McMaster University | former Associate Professor - Physiological Sciences
Most Relevant Research Interests
Oncology
Other Research Interests (39)
skeletal muscle
nutrition
physical activity
obesity
cancer
And 34 more
About
Dr. Everson A Nunes is a highly accomplished researcher and educator in the field of physiological sciences. He received his Ph.D. in Cellular and Molecular Biology with a focus on Physiological Sciences from Universidade Federal do Paraná in 2009, after completing a BSc in Human Nutrition and an MSc in Physiological Sciences. He also holds a specialization in Exercise Physiology and a BSc in Biological Sciences from Universidade Federal do Paraná. Dr. Nunes has a strong background in research, having completed two post-doctoral fellowships at McMaster University and Universidade Federal do Paraná. He has also held positions as an associate professor and assistant professor at Universidade Federal de Santa Catarina. He has published numerous articles in peer-reviewed journals, and his research focuses on the effects of exercise and nutrition on physiological processes in the human body. In addition to his research, Dr. Nunes is also a dedicated educator. He has taught at various universities in Brazil, including Universidade Federal de Santa Catarina, Universidade Gama Filho, Faculdades Integradas Espírita, Pontificia Universidade Católica do Paraná, and Faculdade do Litoral Sul. He is known for his dynamic teaching style and his ability to engage students in complex physiological concepts. Dr. Nunes is a member of several professional organizations, including the American Society for Nutrition, the Canadian Society of Exercise Physiology, the Canadian Nutrition Society and the Brazilian Society of Physiology. He is also a regular speaker at national and international conferences, sharing his expertise and research findings with colleagues and students. Overall, Dr. Nunes is a highly qualified and experienced professional in physiological sciences, metabolism, cancer and nutrition. His dedication to research and education makes him a valuable asset to any institution.
Most Relevant Publications (6+)

97 total publications

Does Oil Rich in Alpha-Linolenic Fatty Acid Cause the Same Immune Modulation as Fish Oil in Walker 256 Tumor-Bearing Rats?

Nutrition and Cancer / Sep 21, 2016

Schiessel, D. L., Yamazaki, R. K., Kryczyk, M., Coelho de Castro, I., Yamaguchi, A. A., Pequito, D. C. T., Brito, G. A. P., Borghetti, G., Aikawa, J., Nunes, E. A., Naliwaiko, K., & Fernandes, L. C. (2016). Does Oil Rich in Alpha-Linolenic Fatty Acid Cause the Same Immune Modulation as Fish Oil in Walker 256 Tumor-Bearing Rats? Nutrition and Cancer, 68(8), 1369–1380. https://doi.org/10.1080/01635581.2016.1224364

Fish oil supplementation during chemotherapy increases posterior time to tumor progression in colorectal cancer

Nutrition and Cancer / Dec 23, 2015

Camargo, C. de Q., Mocellin, M. C., Pastore Silva, J. de A., Fabre, M. E. de S., Nunes, E. A., & Trindade, E. B. S. de M. (2015). Fish oil supplementation during chemotherapy increases posterior time to tumor progression in colorectal cancer. Nutrition and Cancer, 68(1), 70–76. https://doi.org/10.1080/01635581.2016.1115097

Individuals with Hematological Malignancies Before Undergoing Chemotherapy Present Oxidative Stress Parameters and Acute Phase Proteins Correlated with Nutritional Status

Nutrition and Cancer / Feb 24, 2015

Camargo, C. de Q., Borges, D. da S., Oliveira, P. F. de, Chagas, T. R., Del Moral, J. A. G., Durigon, G. S., Dias, B. V., Vieira, A. G., Gaspareto, P., Trindade, E. B. S. de M., & Nunes, E. A. (2015). Individuals with Hematological Malignancies Before Undergoing Chemotherapy Present Oxidative Stress Parameters and Acute Phase Proteins Correlated with Nutritional Status. Nutrition and Cancer, 67(3), 463–471. https://doi.org/10.1080/01635581.2015.1004732

Exercise and Shark Liver Oil Supplementation Reduce Tumor Growth and Cancer Cachexia in Walker 256 Tumor Bearing Rats

Journal of Cancer Science & Therapy / Jan 01, 2014

Bordignon, J. (2014). Exercise and Shark Liver Oil Supplementation Reduce Tumor Growth and Cancer Cachexia in Walker 256 Tumor Bearing Rats. Journal of Cancer Science & Therapy, 06(03). https://doi.org/10.4172/1948-5956.1000254

Bax/Bcl-2 Protein Expression Ratio and Leukocyte Function Are Related to Reduction of Walker-256 Tumor Growth After β-Hydroxy-β-Methylbutyrate (HMB) Administration in Wistar Rats

Nutrition and Cancer / Feb 01, 2012

Kuczera, D., Paro de Oliveira, H. H., Fonseca Guimarães, F. de S., de Lima, C., Alves, L., Machado, A. F., Coelho, I., Yamaguchi, A., Donatti, L., Naliwaiko, K., Fernandes, L. C., & Nunes, E. A. (2012). Bax/Bcl-2 Protein Expression Ratio and Leukocyte Function Are Related to Reduction of Walker-256 Tumor Growth After β-Hydroxy-β-Methylbutyrate (HMB) Administration in Wistar Rats. Nutrition and Cancer, 64(2), 286–293. https://doi.org/10.1080/01635581.2012.647229

Ratio of n6 to n-3 Fatty Acids in the Diet Affects Tumor Growth and Cachexia in Walker 256 Tumor-Bearing Rats

Nutrition and Cancer / Nov 01, 2005

Pizato, N., Bonatto, S., Yamazaki, R. K., Aikawa, J., Nogata, C., Mund, R. C., Nunes, E. A., Piconcelli, M., Naliwaiko, K., Curi, R., Calder, P. C., & Fernandes, L. C. (2005). Ratio of n6 to n-3 Fatty Acids in the Diet Affects Tumor Growth and Cachexia in Walker 256 Tumor-Bearing Rats. Nutrition and Cancer, 53(2), 194–201. https://doi.org/10.1207/s15327914nc5302_8

See Full Profile

Dr. Shilpa Patil, Ph.D

Vancouver, British Columbia, Canada
PhD & Postdoc level expertise in Cancer Research
Most Relevant Research Interests
Oncology
Other Research Interests (11)
Cancer
epigenetics
development
Cancer Research
Biophysics
And 6 more
About
Dr. Shilpa Patil is a highly experienced cancer researcher with a strong background in Preclinical studies. She received her Ph.D. in Molecular Medicine from the University of Göttingen in 2020, where she focused on developing novel treatments for pancreatic cancer. Prior to that, she completed her MSc in Regenerative Medicine from Manipal University in 2014 and her BSc in Biotechnology from the same institution in 2012. With over 6 years of research experience, Dr. Patil has worked at prestigious institutions such as the University of British Columbia, University of Göttingen and JNCASR. Her expertise lies in the areas of cancer biology, epigenetics, cell and molecular biology, and regenerative medicine. She has published numerous research articles in reputed journals and has presented her work at various international conferences. Dr. Patil is a dedicated and passionate scientist, committed to using her knowledge and skills to contribute to the fight against cancer. She is driven by her curiosity to unravel complex biological processes and her desire to make a positive impact in the field of cancer research. She is also driven to bridge the academia-industry gap.
Most Relevant Publications (3+)

20 total publications

EZH2 Regulates Pancreatic Cancer Subtype Identity and Tumor Progression via Transcriptional Repression of GATA6

Cancer Research / Nov 01, 2020

Patil, S., Steuber, B., Kopp, W., Kari, V., Urbach, L., Wang, X., Küffer, S., Bohnenberger, H., Spyropoulou, D., Zhang, Z., Versemann, L., Bösherz, M. S., Brunner, M., Gaedcke, J., Ströbel, P., Zhang, J.-S., Neesse, A., Ellenrieder, V., Singh, S. K., … Hessmann, E. (2020). EZH2 Regulates Pancreatic Cancer Subtype Identity and Tumor Progression via Transcriptional Repression of GATA6. Cancer Research, 80(21), 4620–4632. https://doi.org/10.1158/0008-5472.can-20-0672

TP53-Status-Dependent Oncogenic EZH2 Activity in Pancreatic Cancer

Cancers / Jul 15, 2022

Versemann, L., Patil, S., Steuber, B., Zhang, Z., Kopp, W., Krawczyk, H. E., Kaulfuß, S., Wollnik, B., Ströbel, P., Neesse, A., Singh, S. K., Ellenrieder, V., & Hessmann, E. (2022). TP53-Status-Dependent Oncogenic EZH2 Activity in Pancreatic Cancer. Cancers, 14(14), 3451. https://doi.org/10.3390/cancers14143451

HSP90 Inhibition Synergizes with Cisplatin to Eliminate Basal-like Pancreatic Ductal Adenocarcinoma Cells

Cancers / Dec 07, 2021

Ewers, K. M., Patil, S., Kopp, W., Thomale, J., Quilitz, T., Magerhans, A., Wang, X., Hessmann, E., & Dobbelstein, M. (2021). HSP90 Inhibition Synergizes with Cisplatin to Eliminate Basal-like Pancreatic Ductal Adenocarcinoma Cells. Cancers, 13(24), 6163. https://doi.org/10.3390/cancers13246163

See Full Profile

Boris Leibovitch

New York, New York, United States of America
Experienced wet lab and in teaching Molecular Cell biologist, geneticist, cancer biologist in Academia
Most Relevant Research Interests
Oncology
Other Research Interests (8)
Cancer Research
Cell Biology
Developmental Biology
Molecular Biology
Hematology
And 3 more
About
I am experienced molecular and cell biologist with deep genetics background who worked many years in USA and Russia on the bench and as teacher. Both types of work had demanded extremely broad knowledge and understanding of developments in the fields. Participation in grant writing, editorial/reviewer work for scientific journals and consulting colleagues on these subjects added a lot to my broad experience as the scientist.
Most Relevant Publications (5+)

22 total publications

Targeted interference of SIN3A-TGIF1 function by SID decoy treatment inhibits Wnt signaling and invasion in triple negative breast cancer cells

Oncotarget / Aug 19, 2016

Kwon, Y.-J., Leibovitch, B. A., Bansal, N., Pereira, L., Chung, C.-Y., Ariztia, E. V., Zelent, A., Farias, E. F., & Waxman, S. (2016). Targeted interference of SIN3A-TGIF1 function by SID decoy treatment inhibits Wnt signaling and invasion in triple negative breast cancer cells. Oncotarget, 8(51), 88421–88436. https://doi.org/10.18632/oncotarget.11381

Blocking the PAH2 domain of Sin3A inhibits tumorigenesis and confers retinoid sensitivity in triple negative breast cancer

Oncotarget / Jun 07, 2016

Bansal, N., Bosch, A., Leibovitch, B., Pereira, L., Cubedo, E., Yu, J., Pierzchalski, K., Jones, J. W., Fishel, M., Kane, M., Zelent, A., Waxman, S., & Farias, E. (2016). Blocking the PAH2 domain of Sin3A inhibits tumorigenesis and confers retinoid sensitivity in triple negative breast cancer. Oncotarget, 7(28), 43689–43702. https://doi.org/10.18632/oncotarget.9905

Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer

Molecular Cancer Therapeutics / Aug 01, 2015

Kwon, Y.-J., Petrie, K., Leibovitch, B. A., Zeng, L., Mezei, M., Howell, L., Gil, V., Christova, R., Bansal, N., Yang, S., Sharma, R., Ariztia, E. V., Frankum, J., Brough, R., Sbirkov, Y., Ashworth, A., Lord, C. J., Zelent, A., Farias, E., … Waxman, S. (2015). Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer. Molecular Cancer Therapeutics, 14(8), 1824–1836. https://doi.org/10.1158/1535-7163.mct-14-0980-t

Targeting the SIN3A-PF1 interaction inhibits epithelial to mesenchymal transition and maintenance of a stem cell phenotype in triple negative breast cancer

Oncotarget / Oct 09, 2015

Bansal, N., Petrie, K., Christova, R., Chung, C.-Y., Leibovitch, B. A., Howell, L., Gil, V., Sbirkov, Y., Lee, E., Wexler, J., Ariztia, E. V., Sharma, R., Zhu, J., Bernstein, E., Zhou, M.-M., Zelent, A., Farias, E., & Waxman, S. (2015). Targeting the SIN3A-PF1 interaction inhibits epithelial to mesenchymal transition and maintenance of a stem cell phenotype in triple negative breast cancer. Oncotarget, 6(33), 34087–34105. https://doi.org/10.18632/oncotarget.6048

Invasive phenotype in triple negative breast cancer is inhibited by blocking SIN3A–PF1 interaction through KLF9 mediated repression of ITGA6 and ITGB1

Translational Oncology / Feb 01, 2022

Kadamb, R., Leibovitch, B. A., Farias, E. F., Dahiya, N., Suryawanshi, H., Bansal, N., & Waxman, S. (2022). Invasive phenotype in triple negative breast cancer is inhibited by blocking SIN3A–PF1 interaction through KLF9 mediated repression of ITGA6 and ITGB1. Translational Oncology, 16, 101320. https://doi.org/10.1016/j.tranon.2021.101320

See Full Profile

Luca Delfinis

Toronto, Ontario, Canada
PhD candidate in physiology researching the mechanisms that drive muscle dysfunction in cancer
Research Interests (3)
Physiology
Physiology (medical)
Cell Biology
About
Luca Delfinis is a PhD candidate at York University where his research focuses on muscle dysfunction in cancer. Luca has been a part of several research collaborations both nationally and internationally throughout his PhD that has helped him gain unique perspectives in physiology, especially in the context of metabolism. He has also presented at several conferences where he has discussed data with leaders in cachexia, metabolism, exercise and more.

See Full Profile

Dr. Michael W. Craige, PhD, MBA

New York
Entrepreneurial Scientist | Research Technology, Informatics & Data Science
Most Relevant Research Interests
Oncology
Other Research Interests (5)
Biomedical Informatics
Computational Biology
Neuroinformatics
Bioinformatics
Cancer Research
About
Dr. Michael W. Craige is a research scientist and fellow, leveraging his expertise in biomedical informatics, data science, intellectual property law, and innovation strategy to assess patent, and license new inventions and technologies reported by scientists. He has contributed to publications in high-impact journals, such as Nature Communications and Frontiers in Oncology, and has helped several startups secure their first institutional venture capital funding. His professional journey encompasses a rich blend of roles, including an NSF I-Corps Startup Mentor at Rutgers Office of Innovation Ventures, his recent tenure as a Venture Capital Fellow at SOSV's IndieBio in New York, and training in intellectual property law as a patent agent at Casimir Jones Law Firm. Dr. Craige received his MBA from The Georgia Institute of Technology and his PhD in Biomedical Informatics at Rutgers University where he’s developing computational methods for high-throughput cancer genomic data analysis, including statistical models for elucidating the mechanisms of prostate cancer disease progression and therapeutic response. During his doctoral program, he focused his research on pediatric neurology to understand the underline molecular mechanism of epilepsy in infants, jointly at Emory and Rutgers University. Dr. Craige was the managing director and ex-founder at CiDrep Informatics, a health and scientific-informatics consulting firm, that operated across the US and Canada.
Most Relevant Publications (1+)

3 total publications

Tissue-specific biological aging predicts progression in prostate cancer and acute myeloid leukemia

Frontiers in Oncology / Sep 06, 2023

Ramakrishnan, A., Datta, I., Panja, S., Patel, H., Liu, Y., Craige, M. W., Chu, C., Jean-Marie, G., Oladoja, A.-R., Kim, I., & Mitrofanova, A. (2023). Tissue-specific biological aging predicts progression in prostate cancer and acute myeloid leukemia. Frontiers in Oncology, 13. https://doi.org/10.3389/fonc.2023.1222168

See Full Profile

Dushani L. Palliyaguru, Ph.D.

Baltimore, MD, Maryland, United States of America
Toxicologist | Aging, Nutrition and Metabolism Research Scientist | Systems Biologist
Most Relevant Research Interests
Oncology
Other Research Interests (16)
Nutrition
aging
Hematology
Molecular Biology
Food Science
And 11 more
About
·   Highly productive scientist with 13 years of multidisciplinary experience in toxicology, molecular nutrition, and aging/ disease biomarkers ·   Excellent communicator with proven record of advanced writing and presentation skills - manuscripts, conference presentations, and grants ·   Extensive experience in large study design, supervision and coordination, big data analysis, and management of junior scientists
Most Relevant Publications (1+)

21 total publications

Frugal chemoprevention: targeting Nrf2 with foods rich in sulforaphane

Seminars in Oncology / Feb 01, 2016

Yang, L., Palliyaguru, D. L., & Kensler, T. W. (2016). Frugal chemoprevention: targeting Nrf2 with foods rich in sulforaphane. Seminars in Oncology, 43(1), 146–153. https://doi.org/10.1053/j.seminoncol.2015.09.013

See Full Profile

Michael W Harman

East Greenwich, RI, Rhode Island, United States of America
Distinguished Subject Matter Expert & Leader in Medical Technologies.
Most Relevant Research Interests
Oncology
Other Research Interests (13)
Bacteria & Cell Bio-Physics
Biomechanics
Infectious Diseases
Immunology
Microbiology
And 8 more
About
Highly skilled, energetic, and motivated professional empowered by over a decade of cross-disciplinary engineering and scientific applications experience. Presenting elegant solutions to prevalent biomedical challenges. Motivated by driving deliverable outcomes from complex research studies through effective leadership, active consulting work, and innovative problem-solving techniques. Seeking to make an immediate impact in a fast-paced biotechnology environment capitalizing on my advanced comprehension, continued professional growth, strategic product development expertise, and active network of personal connections across all areas of science, engineering, medicine, manufacturing and healthcare.
Most Relevant Publications (2+)

15 total publications

Abstract 3591: Expression of 14-3-3 gamma stabilizes polyploidization in NSCLC cells

Cancer Research / Jul 15, 2016

Gomes, C. J., Harman, M., Centuori, S., Wolgemuth, C., & Martinez, J. (2016). Abstract 3591: Expression of 14-3-3 gamma stabilizes polyploidization in NSCLC cells. Cancer Research, 76(14_Supplement), 3591–3591. https://doi.org/10.1158/1538-7445.am2016-3591

Abstract 2066: Aberrant upregulation of 14-3-3 gamma promotes mononucleated polyploidization in human lung cancers

Cancer Research / Aug 01, 2015

Gomes, C. J., Harman, M., Martinez, J., & Centuori, S. (2015). Abstract 2066: Aberrant upregulation of 14-3-3 gamma promotes mononucleated polyploidization in human lung cancers. Cancer Research, 75(15_Supplement), 2066–2066. https://doi.org/10.1158/1538-7445.am2015-2066

See Full Profile

Burcu Vitrinel, Ph.D.

San Francisco
Cross-functional life sciences strategy professional with a Ph.D. in genetics
Most Relevant Research Interests
Oncology
Other Research Interests (15)
Molecular Biology
Biochemistry
Cell Biology
Aging
Computer Science Applications
And 10 more
About
Cross-functional life sciences **strategy** professional with a doctoral degree in **genetics**; worked on 16+ projects in collaboration with 7+ big pharma clients as the lead consultant in a **client-facing** role. Exceptional understanding of current life sciences **market trends**. Scientist with 10+ years of wet-lab with hands-on **CRISPR-Cas9 gene** **editing and tandem mass-spectrometry** experience with 3 first-author papers. Experienced primary market researcher for pharmaceutical companies. Award-winning science communicator for a wide range of audiences tailored to different internal and external stakeholders.

See Full Profile

John M Baust, Ph.D

Ithaca, New York, United States of America
Proven success in delivering best-in-class services across scientific, commercial and education environments.
Most Relevant Research Interests
Oncology
Other Research Interests (16)
Cell Biology
Biotechnology
Biomedical Engineering
Transplantation
Surgery
And 11 more
About
***Proven success in delivering best-in-class services across highly regulated scientific and commercial environments.*** * Resourceful, dynamic, and future-focused professional; equipped with strategic leadership, business, research, and academic expertise with career excellence in conducting in-depth research, leading multi-faceted R&D projects, and developing new products and treatments. * Dedicated, driven self-starter focused on developing innovative life changing technologies and procedures advancing the areas of cancer treatment, regenerative medicine and cell therapy.   * Substantial experience in providing oversight for medical device development, pre-clinical studies, cancer therapy, stem cell preservation, cell therapy, tissue engineering, and organ transplantation, etc. * Astute at establishing solid relationships with stakeholders and industry leaders to drive innovative ideas and lead collaborative efforts in pursuit of accomplishing long-term milestones. * Successful in delivering interactive academic instruction across higher education settings offering captivating lectures on Biology and Entrepreneurship courses in accordance with the organizational mission. * Accredited with authoring, managing, and executing multi-million dollar grants, corporate contracts * Accomplished author of numerous patents and high profile publications to disseminate essential research findings.
Most Relevant Publications (14+)

68 total publications

Issues Critical to the Successful Application of Cryosurgical Ablation of the Prostate

Technology in Cancer Research & Treatment / Apr 01, 2007

Baust, J. G., Gage, A. A., Klossner, D., Clarke, D., Miller, R., Cohen, J., Katz, A., Polascik, T., Clarke, H., & Baust, J. M. (2007). Issues Critical to the Successful Application of Cryosurgical Ablation of the Prostate. Technology in Cancer Research & Treatment, 6(2), 97–109. https://doi.org/10.1177/153303460700600206

Cryoablation of Renal Cancer: Variables Involved in Freezing-Induced Cell Death

Technology in Cancer Research & Treatment / Apr 01, 2007

Clarke, D. M., Robilotto, A. T., Rhee, E., VanBuskirk, R. G., Baust, J. G., Gage, A. A., & Baust, J. M. (2007). Cryoablation of Renal Cancer: Variables Involved in Freezing-Induced Cell Death. Technology in Cancer Research & Treatment, 6(2), 69–79. https://doi.org/10.1177/153303460700600203

Development of a Tissue Engineered Human Prostate Tumor Equivalent for Use in the Evaluation of Cryoablative Techniques

Technology in Cancer Research & Treatment / Apr 01, 2007

Robilotto, A. T., Clarke, D., Baust, J. M., Van Buskirk, R. G., Gage, A. A., & Baust, J. G. (2007). Development of a Tissue Engineered Human Prostate Tumor Equivalent for Use in the Evaluation of Cryoablative Techniques. Technology in Cancer Research & Treatment, 6(2), 81–89. https://doi.org/10.1177/153303460700600204

Integrin involvement in freeze resistance of androgen-insensitive prostate cancer

Prostate Cancer and Prostatic Diseases / Jan 12, 2010

Baust, J. G., Klossner, D. P., VanBuskirk, R. G., Gage, A. A., Mouraviev, V., Polascik, T. J., & Baust, J. M. (2010). Integrin involvement in freeze resistance of androgen-insensitive prostate cancer. Prostate Cancer and Prostatic Diseases, 13(2), 151–161. https://doi.org/10.1038/pcan.2009.59

Use of 1,25α dihydroxyvitamin D3 as a cryosensitizing agent in a murine prostate cancer model

Prostate Cancer and Prostatic Diseases / Jan 11, 2011

Santucci, K. L., Snyder, K. K., Baust, J. M., Van Buskirk, R. G., Mouraviev, V., Polascik, T. J., Gage, A. A., & Baust, J. G. (2011). Use of 1,25α dihydroxyvitamin D3 as a cryosensitizing agent in a murine prostate cancer model. Prostate Cancer and Prostatic Diseases, 14(2), 97–104. https://doi.org/10.1038/pcan.2010.52

Temperature-dependent activation of differential apoptotic pathways during cryoablation in a human prostate cancer model

Prostate Cancer and Prostatic Diseases / Dec 11, 2012

Robilotto, A. T., Baust, J. M., Van Buskirk, R. G., Gage, A. A., & Baust, J. G. (2012). Temperature-dependent activation of differential apoptotic pathways during cryoablation in a human prostate cancer model. Prostate Cancer and Prostatic Diseases, 16(1), 41–49. https://doi.org/10.1038/pcan.2012.48

Re-purposing cryoablation: a combinatorial ‘therapy’ for the destruction of tissue

Prostate Cancer and Prostatic Diseases / Jan 27, 2015

Baust, J. G., Bischof, J. C., Jiang-Hughes, S., Polascik, T. J., Rukstalis, D. B., Gage, A. A., & Baust, J. M. (2015). Re-purposing cryoablation: a combinatorial ‘therapy’ for the destruction of tissue. Prostate Cancer and Prostatic Diseases, 18(2), 87–95. https://doi.org/10.1038/pcan.2014.54

Characterization of Pancreatic Cancer Cell Thermal Response to Heat Ablation or Cryoablation

Technology in Cancer Research & Treatment / Jun 23, 2016

Baumann, K. W., Baust, J. M., Snyder, K. K., Baust, J. G., & Van Buskirk, R. G. (2016). Characterization of Pancreatic Cancer Cell Thermal Response to Heat Ablation or Cryoablation. Technology in Cancer Research & Treatment, 16(4), 393–405. https://doi.org/10.1177/1533034616655658

Investigation of the Impact of Cell Cycle Stage on Freeze Response Sensitivity of Androgen-Insensitive Prostate Cancer

Technology in Cancer Research & Treatment / Jul 08, 2016

Santucci, K. L., Baust, J. M., Snyder, K. K., Van Buskirk, R. G., & Baust, J. G. (2016). Investigation of the Impact of Cell Cycle Stage on Freeze Response Sensitivity of Androgen-Insensitive Prostate Cancer. Technology in Cancer Research & Treatment, 15(4), 609–617. https://doi.org/10.1177/1533034616648059

Assessment of Cryosurgical Device Performance Using a 3D Tissue-Engineered Cancer Model

Technology in Cancer Research & Treatment / May 17, 2017

Baust, J. M., Robilotto, A., Snyder, K. K., Santucci, K., Stewart, J., Van Buskirk, R., & Baust, J. G. (2017). Assessment of Cryosurgical Device Performance Using a 3D Tissue-Engineered Cancer Model. Technology in Cancer Research & Treatment, 16(6), 900–909. https://doi.org/10.1177/1533034617708960

Dose Escalation of Vitamin D3 Yields Similar Cryosurgical Outcome to Single Dose Exposure in a Prostate Cancer Model

Cancer Control / Jan 01, 2018

Santucci, K. L., Baust, J. M., Snyder, K. K., Van Buskirk, R. G., & Baust, J. G. (2018). Dose Escalation of Vitamin D3 Yields Similar Cryosurgical Outcome to Single Dose Exposure in a Prostate Cancer Model. Cancer Control, 25(1), 107327481875741. https://doi.org/10.1177/1073274818757418

Defeating Cancers’ Adaptive Defensive Strategies Using Thermal Therapies: Examining Cancer’s Therapeutic Resistance, Ablative, and Computational Modeling Strategies as a means for Improving Therapeutic Outcome

Technology in Cancer Research & Treatment / Jan 01, 2018

Baust, J. M., Rabin, Y., Polascik, T. J., Santucci, K. L., Snyder, K. K., Van Buskirk, R. G., & Baust, J. G. (2018). Defeating Cancers’ Adaptive Defensive Strategies Using Thermal Therapies: Examining Cancer’s Therapeutic Resistance, Ablative, and Computational Modeling Strategies as a means for Improving Therapeutic Outcome. Technology in Cancer Research & Treatment, 17, 153303381876220. https://doi.org/10.1177/1533033818762207

Evaluation of a Novel Cystoscopic Compatible Cryocatheter for the Treatment of Bladder Cancer

Bladder Cancer / Sep 21, 2020

Baust, J. M., Robilotto, A., Santucci, K. L., Snyder, K. K., Van Buskirk, R. G., Katz, A., Corcoran, A., & Baust, J. G. (2020). Evaluation of a Novel Cystoscopic Compatible Cryocatheter for the Treatment of Bladder Cancer. Bladder Cancer, 6(3), 303–318. https://doi.org/10.3233/blc-200321

Breast Cancer Cryoablation: Assessment of the Impact of Fundamental Procedural Variables in an In Vitro Human Breast Cancer Model

Breast Cancer: Basic and Clinical Research / Jan 01, 2020

Snyder, K. K., Van Buskirk, R. G., Baust, J. G., & Baust, J. M. (2020). Breast Cancer Cryoablation: Assessment of the Impact of Fundamental Procedural Variables in an In Vitro Human Breast Cancer Model. Breast Cancer: Basic and Clinical Research, 14, 117822342097236. https://doi.org/10.1177/1178223420972363

See Full Profile

Garrett A. Perchetti, Research Scientist - Virology

New York
Research Scientist and MD Candidate in virology with publications on infectious diseases, laboratory medicine, viral genetics, and clinical medicine
Most Relevant Research Interests
Oncology
Other Research Interests (14)
Virology
Microbiology
Infectious Diseases
SARS-CoV-2
COVID-19
And 9 more
About
Garrett A. Perchetti is a highly accomplished research scientist in the field of virology. He received a Bachelor of Science in Microbiology and a Bachelor of Arts in Art History from the University of Washington. His interest in both science and the arts led him to pursue a career in virology, where he could combine his passion for understanding the natural world with his creative thinking skills. After completing his undergraduate studies, Garrett continued his education by earning a Medical Degree from Ross University School of Medicine in 2025. During his time in medical school, he developed a keen interest in virology and infectious diseases, which ultimately led him to specialize in this field. Garrett's educational background is complemented by his extensive experience as a research scientist. He has worked at the University of Washington School of Medicine, where he has conducted groundbreaking research on various types of viruses. His work has been published in numerous scientific journals, and he has presented his findings at international conferences. Garrett's contributions to the field of virology have been widely recognized, and he has received several awards and accolades for his work. He is known for his meticulous attention to detail, innovative thinking, and ability to collaborate effectively with other researchers. In his free time, Garrett enjoys painting, hiking, and traveling. He is also passionate about raising awareness about the importance of vaccinations and promoting public health initiatives. With his exceptional education and extensive experience, Garrett A. Perchetti is a valuable asset to the field of virology and will continue to make significant contributions in the future.
Most Relevant Publications (2+)

28 total publications

20. Risk Factors for Breakthrough Cytomegalovirus (CMV) Infection and De Novo Resistance in Hematopoietic Cell Transplantation (HCT) Recipients Receiving Letermovir Prophylaxis

Open Forum Infectious Diseases / Nov 01, 2021

Zamora, D., Perchetti, G., Biernacki, M., Xie, H., Castor, J. L., Joncas-schronce, L., Blazevic, R., Leisenring, W., Huang, M.-L., Jerome, K., Martin, P. J., Boeckh, M., & Greninger, A. L. (2021). 20. Risk Factors for Breakthrough Cytomegalovirus (CMV) Infection and De Novo Resistance in Hematopoietic Cell Transplantation (HCT) Recipients Receiving Letermovir Prophylaxis. Open Forum Infectious Diseases, 8(Supplement_1), S13–S14. https://doi.org/10.1093/ofid/ofab466.020

2626. Rhinovirus in Children Presenting to the Emergency Department: Role of Viral Load in Disease Severity and Co-Infections

Open Forum Infectious Diseases / Oct 01, 2019

Waghmare, A., Strelitz, B., Lacombe, K., Perchetti, G., Nalla, A., Rha, B., Midgley, C., Lively, J. Y., Klein, E. J., Kuypers, J., & Englund, J. A. (2019). 2626. Rhinovirus in Children Presenting to the Emergency Department: Role of Viral Load in Disease Severity and Co-Infections. Open Forum Infectious Diseases, 6(Supplement_2), S915–S916. https://doi.org/10.1093/ofid/ofz360.2304

See Full Profile

Jeffrey Townsend

New Haven, CT
Professor of Biostatistics and Ecology & Evolutionary Biology
Most Relevant Research Interests
Oncology
Other Research Interests (52)
Evolutionary Genomics
Microbiology
Infectious Diseases
Genetics
Cell Biology
And 47 more
About
Jeffrey Townsend is a Professor of Organismic and Evolutionary Biology at Yale University. He received his Ph.D. from Harvard University in 2002 and his Sc.B. from Brown University in 1994. He has been a teacher at St. Ann's School and an Assistant Professor at the University of Connecticut. He is currently the Elihu Professor of Biostatistics at Yale University.
Most Relevant Publications (21+)

207 total publications

Estimation of Neutral Mutation Rates and Quantification of Somatic Variant Selection Using cancereffectsizeR

Cancer Research / Dec 05, 2022

Mandell, J. D., Cannataro, V. L., & Townsend, J. P. (2022). Estimation of Neutral Mutation Rates and Quantification of Somatic Variant Selection Using cancereffectsizeR. Cancer Research, 83(4), 500–505. https://doi.org/10.1158/0008-5472.can-22-1508

In Response to “De Novo KRAS G12C-Mutant SCLC: A Case Report”

JTO Clinical and Research Reports / Dec 01, 2022

Moore, M., Zhuo, Y., Mandell, J. D., Gaffney, S. G., & Townsend, J. P. (2022). In Response to “De Novo KRAS G12C-Mutant SCLC: A Case Report.” JTO Clinical and Research Reports, 3(12), 100418. https://doi.org/10.1016/j.jtocrr.2022.100418

Not only mutations but also tumorigenesis can be substantially attributed to DNA damage from reactive oxygen species in RUNX1::RUNX1T1-fusion-positive acute myeloid leukemia

Leukemia / Nov 11, 2022

Mandell, J. D., Fisk, J. N., Cyrenne, E., Xu, M. L., Cannataro, V. L., & Townsend, J. P. (2022). Not only mutations but also tumorigenesis can be substantially attributed to DNA damage from reactive oxygen species in RUNX1::RUNX1T1-fusion-positive acute myeloid leukemia. Leukemia, 36(12), 2931–2933. https://doi.org/10.1038/s41375-022-01752-5

Cancer Relevance of Human Genes

JNCI: Journal of the National Cancer Institute / Apr 13, 2022

Qing, T., Mohsen, H., Cannataro, V. L., Marczyk, M., Rozenblit, M., Foldi, J., Murray, M., Townsend, J. P., Kluger, Y., Gerstein, M., & Pusztai, L. (2022). Cancer Relevance of Human Genes. JNCI: Journal of the National Cancer Institute, 114(7), 988–995. https://doi.org/10.1093/jnci/djac068

Quarantine and testing strategies to ameliorate transmission due to travel during the COVID-19 pandemic: a modelling study

The Lancet Regional Health - Europe / Mar 01, 2022

Wells, C. R., Pandey, A., Fitzpatrick, M. C., Crystal, W. S., Singer, B. H., Moghadas, S. M., Galvani, A. P., & Townsend, J. P. (2022). Quarantine and testing strategies to ameliorate transmission due to travel during the COVID-19 pandemic: a modelling study. The Lancet Regional Health - Europe, 14, 100304. https://doi.org/10.1016/j.lanepe.2021.100304

Premetastatic shifts of endogenous and exogenous mutational processes support consolidative therapy in EGFR-driven lung adenocarcinoma

Cancer Letters / Feb 01, 2022

Fisk, J. N., Mahal, A. R., Dornburg, A., Gaffney, S. G., Aneja, S., Contessa, J. N., Rimm, D., Yu, J. B., & Townsend, J. P. (2022). Premetastatic shifts of endogenous and exogenous mutational processes support consolidative therapy in EGFR-driven lung adenocarcinoma. Cancer Letters, 526, 346–351. https://doi.org/10.1016/j.canlet.2021.11.011

Environmental and sex-specific molecular signatures of glioma causation

Neuro-Oncology / May 04, 2021

Claus, E. B., Cannataro, V. L., Gaffney, S. G., & Townsend, J. P. (2021). Environmental and sex-specific molecular signatures of glioma causation. Neuro-Oncology, 24(1), 29–36. https://doi.org/10.1093/neuonc/noab103

Heavy mutagenesis by tobacco leads to lung adenocarcinoma tumors with KRAS G12 mutations other than G12D, leading KRAS G12D tumors—on average—to exhibit a lower mutation burden

Lung Cancer / Apr 01, 2022

Tan, C., Mandell, J. D., Dasari, K., Cannataro, V. L., Alfaro-Murillo, J. A., & Townsend, J. P. (2022). Heavy mutagenesis by tobacco leads to lung adenocarcinoma tumors with KRAS G12 mutations other than G12D, leading KRAS G12D tumors—on average—to exhibit a lower mutation burden. Lung Cancer, 166, 265–269. https://doi.org/10.1016/j.lungcan.2021.10.008

Non-Coding Mutations in Urothelial Bladder Cancer: Biological and Clinical Relevance and Potential Utility as Biomarkers

Bladder Cancer / Jun 11, 2020

Yang, A., Cross, C. N., & Townsend, J. P. (2020). Non-Coding Mutations in Urothelial Bladder Cancer: Biological and Clinical Relevance and Potential Utility as Biomarkers. Bladder Cancer, 6(2), 211–213. https://doi.org/10.3233/blc-200278

Transfer RNA methyltransferase gene NSUN2 mRNA expression modifies the effect of T cell activation score on patient survival in head and neck squamous carcinoma

Oral Oncology / Feb 01, 2020

Lu, L., Gaffney, S. G., Cannataro, V. L., & Townsend, J. (2020). Transfer RNA methyltransferase gene NSUN2 mRNA expression modifies the effect of T cell activation score on patient survival in head and neck squamous carcinoma. Oral Oncology, 101, 104554. https://doi.org/10.1016/j.oraloncology.2019.104554

The landscape of novel and complementary targets for immunotherapy: an analysis of gene expression in the tumor microenvironment

Oncotarget / Jul 16, 2019

Gaffney, S. G., Perry, E. B., Chen, P.-M., Greenstein, A., Kaech, S. M., & Townsend, J. P. (2019). The landscape of novel and complementary targets for immunotherapy: an analysis of gene expression in the tumor microenvironment. Oncotarget, 10(44), 4532–4545. https://doi.org/10.18632/oncotarget.27027

Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck

Clinical Cancer Research / Jun 01, 2019

Lee, J. W., Parameswaran, J., Sandoval-Schaefer, T., Eoh, K. J., Yang, D., Zhu, F., Mehra, R., Sharma, R., Gaffney, S. G., Perry, E. B., Townsend, J. P., Serebriiskii, I. G., Golemis, E. A., Issaeva, N., Yarbrough, W. G., Koo, J. S., & Burtness, B. (2019). Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Research, 25(11), 3430–3442. https://doi.org/10.1158/1078-0432.ccr-18-0440

Somatic evolutionary timings of driver mutations

BMC Cancer / Jan 18, 2018

Gomez, K., Miura, S., Huuki, L. A., Spell, B. S., Townsend, J. P., & Kumar, S. (2018). Somatic evolutionary timings of driver mutations. BMC Cancer, 18(1). https://doi.org/10.1186/s12885-017-3977-y

Effect Sizes of Somatic Mutations in Cancer

JNCI: Journal of the National Cancer Institute / Oct 26, 2018

Cannataro, V. L., Gaffney, S. G., & Townsend, J. P. (2018). Effect Sizes of Somatic Mutations in Cancer. JNCI: Journal of the National Cancer Institute, 110(11), 1171–1177. https://doi.org/10.1093/jnci/djy168

Analysis of mutation, selection, and epistasis: an informed approach to cancer clinical trials

Oncotarget / Apr 27, 2018

Wilkins, J. F., Cannataro, V. L., Shuch, B., & Townsend, J. P. (2018). Analysis of mutation, selection, and epistasis: an informed approach to cancer clinical trials. Oncotarget, 9(32), 22243–22253. https://doi.org/10.18632/oncotarget.25155

CDKN2A Copy Number Loss Is an Independent Prognostic Factor in HPV-Negative Head and Neck Squamous Cell Carcinoma

Frontiers in Oncology / Apr 04, 2018

Chen, W. S., Bindra, R. S., Mo, A., Hayman, T., Husain, Z., Contessa, J. N., Gaffney, S. G., Townsend, J. P., & Yu, J. B. (2018). CDKN2A Copy Number Loss Is an Independent Prognostic Factor in HPV-Negative Head and Neck Squamous Cell Carcinoma. Frontiers in Oncology, 8. https://doi.org/10.3389/fonc.2018.00095

PhyloOncology: Understanding cancer through phylogenetic analysis

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer / Apr 01, 2017

Somarelli, J. A., Ware, K. E., Kostadinov, R., Robinson, J. M., Amri, H., Abu-Asab, M., Fourie, N., Diogo, R., Swofford, D., & Townsend, J. P. (2017). PhyloOncology: Understanding cancer through phylogenetic analysis. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1867(2), 101–108. https://doi.org/10.1016/j.bbcan.2016.10.006

Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function

Annals of Oncology / Jan 01, 2017

Choi, M., Kadara, H., Zhang, J., Parra, E. R., Rodriguez-Canales, J., Gaffney, S. G., Zhao, Z., Behrens, C., Fujimoto, J., Chow, C., Kim, K., Kalhor, N., Moran, C., Rimm, D., Swisher, S., Gibbons, D. L., Heymach, J., Kaftan, E., Townsend, J. P., … Wistuba, I. I. (2017). Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function. Annals of Oncology, 28(1), 83–89. https://doi.org/10.1093/annonc/mdw437

Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up

Annals of Oncology / Jan 01, 2017

Kadara, H., Choi, M., Zhang, J., Parra, E. R., Rodriguez-Canales, J., Gaffney, S. G., Zhao, Z., Behrens, C., Fujimoto, J., Chow, C., Yoo, Y., Kalhor, N., Moran, C., Rimm, D., Swisher, S., Gibbons, D. L., Heymach, J., Kaftan, E., Townsend, J. P., … Herbst, R. S. (2017). Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up. Annals of Oncology, 28(1), 75–82. https://doi.org/10.1093/annonc/mdw436

Inferring the Origin of Metastases from Cancer Phylogenies

Cancer Research / Sep 30, 2015

Hong, W. S., Shpak, M., & Townsend, J. P. (2015). Inferring the Origin of Metastases from Cancer Phylogenies. Cancer Research, 75(19), 4021–4025. https://doi.org/10.1158/0008-5472.can-15-1889

Radiation-Specific Clinical Data Should Be Included in Existing Large-Scale Genomic Datasets

International Journal of Radiation Oncology*Biology*Physics / May 01, 2017

Chen, W. S., Townsend, J. P., & Yu, J. B. (2017). Radiation-Specific Clinical Data Should Be Included in Existing Large-Scale Genomic Datasets. International Journal of Radiation Oncology*Biology*Physics, 98(1), 8–10. https://doi.org/10.1016/j.ijrobp.2017.01.023

See Full Profile

Example oncology projects

How can companies collaborate more effectively with researchers, experts, and thought leaders to make progress on oncology?

Development of Targeted Cancer Therapies

An Oncology expert can collaborate with a pharmaceutical company to develop targeted therapies that specifically attack cancer cells, minimizing side effects and improving patient outcomes.

Identification of Biomarkers for Early Cancer Detection

Working with an Oncology researcher, a diagnostic company can identify biomarkers that indicate the presence of cancer at an early stage, enabling early detection and intervention.

Improving Radiation Therapy Techniques

Collaborating with an Oncology expert, a medical device company can enhance radiation therapy techniques, improving precision and minimizing damage to healthy tissues.

Development of Personalized Treatment Plans

An Oncology researcher can assist a healthcare provider in developing personalized treatment plans for cancer patients, considering individual characteristics and genetic profiles.

Exploring Immunotherapy Approaches

Working with an Oncology expert, a biotech company can explore novel immunotherapy approaches for cancer treatment, harnessing the power of the immune system to fight cancer cells.